Premium
Colestilan monotherapy significantly improves glycaemic control and LDL cholesterol levels in patients with type 2 diabetes: a randomized double‐blind placebo‐controlled study
Author(s) -
Kondo K.,
Kadowaki T.
Publication year - 2010
Publication title -
diabetes, obesity and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.445
H-Index - 128
eISSN - 1463-1326
pISSN - 1462-8902
DOI - 10.1111/j.1463-1326.2009.01159.x
Subject(s) - medicine , placebo , type 2 diabetes , double blind , gastroenterology , diabetes mellitus , cholesterol , endocrinology , incidence (geometry) , ldl cholesterol , randomized controlled trial , physics , alternative medicine , pathology , optics
Aim: To evaluate the plasma glucose‐reducing activity and safety of colestilan, a bile acid sequestrant, in patients with type 2 diabetes. Methods: Patients with fasting plasma glucose (FPG) 7.2–11.1 mmol/l and HbA 1c ≥7.0% were randomly allocated in double‐blind manner to receive colestilan or placebo therapy for 12 weeks. Results: A total of 183 patients entered the double‐blind treatment phase. At 12 weeks, colestilan significantly reduced HbA 1c and FPG vs. placebo by 0.9% and 1.2 mmol/l respectively (both p < 0.001). A significant (p < 0.001) 22.5% reduction of LDL cholesterol was also observed in the 172 patients evaluated (colestilan group: n = 86; placebo group: n = 86). However, no significant reduction of fasting insulin was observed (p = 0.087). No incidence of hypoglycaemia was reported in this study. Conclusion: Colestilan improved glycaemic control and reduced LDL cholesterol levels in patients with type 2 diabetes.